Biotech Stocks At 52-Week Highs - HALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE
Biotech stocks hit 52-week highs Aug. 7, 2026. Halozyme (HALO) rose 20% after Q2 revenue of $481M (+48% Y/Y) and 2026 revenue guidance of $1.83B-$1.91B. Fennec (FENC) reached $11.66 on PEDMARK sales of $15.1M (+71% Y/Y). Avalyn (AVLN) hit $34.15. Amylyx (AMLX) hit $24.60. Chemed (CHE) rose to $552.72 after Q2 revenue $673M (+8.8%) and 2026 growth guidance of 8.25%-9.25%.
How this was made
The 30-second read
Why it matters
Traders can act most directly on HALO and CHE due to explicit financial results and full-year guidance ranges. FENC has a near-term scheduled earnings catalyst. AVLN and AMLX are supported by program status but lack new trial data in the text, reducing immediate repricing confidence.
Market read
The most tradable information is the combination of reported financial prints and explicit guidance (HALO, CHE) plus a dated upcoming earnings release (FENC).
What to watch
For HALO, royalty growth sustainability matters; for CHE, the Medicare cap billing limitation ($7,000) could constrain upside despite guidance.
Background
The article is a multi-name roundup of biotech and healthcare stocks reaching 52-week highs, attributing moves to quarterly results, trial/program milestones, and an upcoming earnings date.
Ticker impact
Halozyme shares jumped 20% and hit a 52-week high after reporting Q2 revenue of $481M and raising 2026 revenue guidance to $1.83B-$1.91B.
Bullish bias for follow-through, with volatility likely around any subsequent commentary on royalty sustainability.
The article provides concrete Q2 results, royalty growth, and a full-year revenue estimate range, which are direct valuation inputs.
Fennec hit a 52-week high after reporting Q1 2026 net sales up 71% to $15.1M, and the article flags Q2 results due Aug. 11.
Near-term upside bias into Aug. 11, but risk of mean reversion if Q2 does not extend the growth rate.
The text includes a specific Q1 datapoint and a scheduled next-results date, but no Q2 numbers yet.
Avalyn reached a 52-week high after trading began on Nasdaq April 30, 2026, and the article notes Phase 2 evaluation for AP01 and AP02.
Likely limited follow-through unless upcoming clinical updates validate the Phase 2 programs.
The article provides program descriptions and a listing date, but no new trial readout or financial print in this text.
Amylyx shares climbed to a 52-week high as the article highlights Phase 3 LUCIDITY evaluation of Avexitide and completion of Phase 1 LUMINA enrollment.
Moderate speculative support, with direction dependent on future trial data rather than this update alone.
The newest facts are trial status and expanded access context, not new data that typically drives repricing.
Chemed hit a 52-week high after Q2 results last month, reporting 8.8% YoY revenue growth to $673M and revising full-year growth to 8.25%-9.25%.
Mild bullish bias for re-rating if investors view guidance as credible, with downside risk if Medicare cap constraints bite.
The article includes specific revenue growth and a revised full-year range, but it is not a same-day earnings release.
Market effects
Biotech and healthcare investors may rotate toward names with near-term financial momentum (HALO, CHE) and upcoming catalysts (FENC).
Primarily US-listed biotech/healthcare sentiment; no explicit cross-region macro linkage in the text.
Limited global spillover indicated; the catalysts described are company-specific.
Counterpoint
Some of the 52-week-high framing (AVLN, AMLX) may reflect positioning and milestone anticipation rather than new efficacy or revenue acceleration.
Key entities
- public_companyHalozyme Therapeutics Inc.
Reported Q2 revenue $481M (+48% YoY), royalty payments $308M (+50%), and 2026 revenue guidance $1.83B-$1.91B.
- public_companyFennec Pharmaceuticals Inc.
Reported Q1 2026 net sales $15.1M (+71% YoY) and is expected to release Q2 results Aug. 11.
- public_companyAvalyn Pharma Inc.
Clinical-stage inhaled-medicine developer; Phase 2 evaluation for AP01 and AP02; began Nasdaq trading April 30, 2026.
- public_companyAmylyx Pharmaceuticals Inc.
Clinical-stage company; Avexitide in Phase 3 LUCIDITY for post-bariatric hypoglycemia; AMX0114 Phase 1 LUMINA enrollment completed.
- public_companyChemed Corporation
Reported Q2 revenue $673M (+8.8% YoY), VITAS patient revenues $443.4M, and revised full-year revenue growth to 8.25%-9.25%.
